New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism
Top Cited Papers
Open Access
- 1 September 2015
- journal article
- review article
- Published by Informa UK Limited in Therapeutics and Clinical Risk Management
- Vol. ume 11, 1449-1456
- https://doi.org/10.2147/tcrm.s92222
Abstract
New insights into the mechanisms of action of aspirin and its use in the prevention and treatment of arterial and venous thromboembolism Ymer H Mekaj,1,2 Fetije T Daci,2 Agon Y Mekaj3 1Institute of Pathophysiology, Faculty of Medicine, University of Prishtina, 2Department of Hemostasis and Thrombosis, National Blood Transfusion Center of Kosovo, 3Clinic of Neurosurgery, Faculty of Medicine, University of Prishtina, Prishtina, Kosovo The antithrombotic action of aspirin has long been recognized. Aspirin inhibits platelet function through irreversible inhibition of cyclooxygenase (COX) activity. Until recently, aspirin has been mainly used for primary and secondary prevention of arterial antithrombotic events. The aim of this study was to review the literature with regard to the various mechanisms of the newly discovered effects of aspirin in the prevention of the initiation and development of venous thrombosis. For this purpose, we used relevant data from the latest numerous scientific studies, including review articles, original research articles, double-blinded randomized controlled trials, a prospective combined analysis, a meta-analysis of randomized trials, evidence-based clinical practice guidelines, and multicenter studies. Aspirin is used in the prevention of venous thromboembolism (VTE), especially the prevention of recurrent VTE in patients with unprovoked VTE who were treated with vitamin K antagonists (VKAs) or with non-vitamin K antagonist oral anticoagulants (NOACs). Numerous studies have shown that aspirin reduces the rate of recurrent VTE in patients, following cessation of VKAs or NOACs. Furthermore, low doses of aspirin are suitable for long-term therapy in patients recovering from orthopedic or other surgeries. Aspirin is indicated for the primary and secondary prevention as well as the treatment of cardiovascular diseases, including acute coronary syndrome, myocardial infarction, peripheral artery disease, acute ischemic stroke, and transient ischemic attack (especially in atrial fibrillation or mechanical heart valves). Aspirin can prevent or treat recurrent unprovoked VTEs as well as VTEs occurring after various surgeries or in patients with malignant disease. Recent trials have suggested that the long-term use of low-dose aspirin is effective not only in the prevention and treatment of arterial thrombosis but also in the prevention and treatment of VTE. Compared with VKAs and NOACs, aspirin has a reduced risk of bleeding. Keywords: arterial thrombosis, cyclooxygenase inhibitor, recurrent VTE, plateletKeywords
This publication has 68 references indexed in Scilit:
- Novel oral Anticoagulants in Non-Valvular Atrial FibrillationCardiovascular & Hematological Agents in Medicinal Chemistry, 2014
- Aspirin for the Prevention of Recurrent Venous ThromboembolismCell Metabolism, 2014
- Aspirin for Preventing Venous ThromboembolismNew England Journal of Medicine, 2013
- Aspirin for Dual Prevention of Venous and Arterial ThrombosisNew England Journal of Medicine, 2012
- Aspirin for Preventing the Recurrence of Venous ThromboembolismNew England Journal of Medicine, 2012
- Primary and Secondary Prevention of Cardiovascular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest, 2012
- Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest, 2012
- Selective Cumulative Inhibition of Platelet Thromboxane Production by Low-dose Aspirin in Healthy SubjectsJCI Insight, 1982
- Aspirin Prophylaxis of Venous Thromboembolism after Total Hip ReplacementNew England Journal of Medicine, 1977
- Vitamin K and the biosynthesis of prothrombin. V. Gamma-carboxyglutamic acids, the vitamin K-dependent structures in prothrombin.Journal of Biological Chemistry, 1975